Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Practice Changing Advances: Expanding the Atopic Dermatitis Armamentarium

Building upon recent breakthroughs in our understanding of the pathologic mechanisms driving atopic dermatitis (AD), the existing pharmacopoeia is ...

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Building upon recent breakthroughs in our understanding of the pathologic mechanisms driving atopic dermatitis (AD), the existing pharmacopoeia is preparing for possible approval by the United States Food and Drug Administration of novel therapies that narrowly target immune dysregulation in moderate-to-severe disease. As a result, clinicians need to be knowledgeable about how these emerging agents modulate immune response in AD, as well as understand the clinical trial data regarding their use in patients with moderate-to-severe disease. Thus, clinicians who treat patients with this condition can be prepared to incorporate emerging therapies into treatment plans for appropriate patients as they become available.

    As a value added-resource, a specialized toolkit will also be included as a supplement to the webcast. The toolkit will provide for clinicians the latest treatment guidelines and updated reference guide. In addition, the toolkit will provide helpful information and resources for families and caregivers.

  • Learning Objectives

    • Evaluate the impact of the burden of disease and recognized comorbidities associated with atopic dermatitis (AD);
    • Describe current approaches to diagnose AD and recognize the benefits and limitations of currently available therapies;
    • Evaluate emerging data on T-cell targeted therapeutics for the management of AD. 
  • Target Audience

    The intended audiences for this activity are physicians and other health care professionals who manage patients with atopic dermatitis.

  • Disclosure of Conflicts of Interest

    Emma Guttman-Yassky, MD, PhD
    Professor of Dermatology and Immunology
    Vice Chair of the Department of Dermatology
    Director of the Center for Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases
    Icahn School of Medicine
    Mount Sinai Medical Center
    New York, New York

    John J. Russell, MD
    Director, Family Medicine Residency Program
    Abington Jefferson Hospital
    Abington, PA

    Disclosure of Conflicts of Interest:
    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. 

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    Emma Guttman-Yassky, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Aana Biosciences;  AbbVie Inc.; Almirall, S.A.; Anacor Pharmaceuticals, Inc.; Celgene Corporation; Dermira Inc.; Galderma Laboratories, L.P.; Glenmark Pharmaceuticals; LEO Pharma Inc.; Kyowa Kirin Pharmaceuticals; Lilly; MedImmune Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; Stiefel Laboratories, Inc.; Vitae Pharmaceuticals, Inc.
    Received grants for clinical research from: Celgene Corporation; Glenmark Pharmaceuticals; Janssen Biotech, Inc.; LEO Pharma Inc.; Medimmune Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc. Vitae Pharmaceuticals.
    Served as an investigator for: Regeneron Pharmaceuticals, Inc.

    John J. Russell, MD receives consulting fees from GALDERMA and speaker bureau fees from Sanofi Pasteur.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    • Susan Tyler, MEd, CMP, CHCP, CME Director, has nothing to disclose.
    • Rick E. Ricer, MD, Professor Emeritus, CME Reviewer, has nothing to disclose.
    • Deborah Cole, BS, Program Coordinator, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instructions

    Instruction for Participation
    There are no fees for participating in and receiving CME credit for this online activity. During the period of February 16, 2017 to February 16, 2018, participants must 1) read the CME information, including the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score of 70% and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • Disclaimer

    Legal Disclaimer
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of ReachMD. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.